Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
1.
Ann Rheum Dis ; 68(9): 1466-9, 2009 Sep.
Article in English | MEDLINE | ID: mdl-18952641

ABSTRACT

OBJECTIVE: To describe and assess the response to short-term etoricoxib as shown by MRI and clinical variables in patients with ankylosing spondylitis (AS) selected for eligibility for anti-tumour necrosis factor therapy. METHODS: In a 6-week open-label study, 22 patients with AS and eligible for biological therapy were treated with 90 mg of etoricoxib daily. Clinical and laboratory parameters were obtained and MRI of the sacroiliac joints and the lower thoracic and lumbar spine performed at baseline and at week 6. The primary end point was the proportion of patients fulfilling the SpondyloArthritis international Society (ASAS) response criteria for biological therapies (ASASBIO) while secondary end points included the change in MRI-determined bone lesions. RESULTS: Eight of 20 completers improved enough to meet the ASASBIO response criteria and most clinical variables improved significantly. Fifteen patients had a total of 63 MRI-detectable lesions; overall, 13/60 lesions with paired scans either resolved completely or improved, while five lesions worsened or appeared during treatment. CONCLUSION: Etoricoxib is an effective symptomatic treatment for patients with AS; however, its effect on MRI-detected lesions is small. Further studies are needed to determine the effect of etoricoxib on MRI-determined bone oedema.


Subject(s)
Cyclooxygenase 2 Inhibitors/therapeutic use , Pyridines/therapeutic use , Spondylitis, Ankylosing/drug therapy , Sulfones/therapeutic use , Adult , Aged , Antirheumatic Agents/therapeutic use , Etoricoxib , Female , Humans , Lumbar Vertebrae/pathology , Magnetic Resonance Imaging , Male , Middle Aged , Sacroiliac Joint/pathology , Severity of Illness Index , Spondylitis, Ankylosing/pathology , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors
2.
Rheumatology (Oxford) ; 47(6): 897-900, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18403400

ABSTRACT

OBJECTIVE: To investigate the long-term response to biological therapies in AS in a real life clinical setting and to quantify non-response and response to 'switching' therapies in these cases. METHODS: All patients prescribed TNF-blocking therapies for AS between 1999 and 2006 were studied. Response was evaluated using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and CRP results. RESULTS: A total of 113 patients (84 males: 29 females, mean age 45 yrs, median disease duration 16 yrs, 87% HLA-B27 positive) were identified. At baseline they had a mean BASDAI of 6.57, BASFI 6.57 and CRP of 31 g/dl. At the end of follow-up, these values had reduced to mean BASDAI of 3.12, BASFI 4.16 and CRP of 7 g/dl. Improvements were sustained for 24 months and beyond with no loss of effect. Only nine patients (8%) suffered side-effects leading to cessation or switching of first-line therapy and non-response occurred in 15 patients (13%) in the long term. Fifteen patients (13%) switched to a second drug and 14 of these (93%) had a significant and sustained response. Outcomes were similar regardless of drug used, duration of disease and HLA-B27 status. CONCLUSION: Treatment of active AS with TNF blockers according to the British Society of Rheumatology guidelines leads to a sustained response for over 2 yrs with most patients tolerating the drugs well. The rate of non-response is significantly lower than that seen in RA and nearly all of these patients respond well to a second-line agent.


Subject(s)
Antirheumatic Agents/therapeutic use , Spondylitis, Ankylosing/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Adult , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Drug Evaluation , Drug Therapy, Combination , Etanercept , Female , Humans , Immunoglobulin G/therapeutic use , Infliximab , Male , Middle Aged , Receptors, Tumor Necrosis Factor/therapeutic use , Retrospective Studies , Severity of Illness Index , Treatment Outcome
3.
Ann Rheum Dis ; 67(5): 717-9, 2008 May.
Article in English | MEDLINE | ID: mdl-18055476

ABSTRACT

OBJECTIVE: To investigate the response to biologic drugs in psoriatic arthritis and to quantify non-response and outcome from switching agents. METHODS: 60 patients (33 men and 27 women, mean age 46 years, median disease duration 16 years) prescribed biologic drugs for psoriatic arthritis between 2001 and 2006 were studied. Response was evaluated using joint counts, C-reactive protein levels and disease activity scores (using 28 joints; DAS28). RESULTS: The mean percentage improvements seen were 56% in tender joint count, 70% in swollen joint count, 64% in C-reactive protein level and 36% in the overall disease activity score. Improvements were sustained beyond 24 months with no loss of effect. Side-effects leading to cessation or switching of first-line therapy were only seen in 5% of patients and non-response occurred in 20% long term. Overall, 90% of patients achieved a significant response, using switching in 20% of cases. Outcomes were similar regardless of drug used, duration of disease and subtype of arthritis. CONCLUSIONS: Treatment of active psoriatic arthritis with anti-tumour necrosis factor agents leads to a sustained response over 3 years with most patients tolerating these drugs well. The rate of non-response is low with the majority of patients responding to second- and third-line therapies.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Psoriatic/drug therapy , Biological Products/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Adult , Analysis of Variance , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antirheumatic Agents/adverse effects , Arthritis, Psoriatic/immunology , Arthritis, Psoriatic/pathology , Biological Products/adverse effects , C-Reactive Protein/analysis , Etanercept , Female , Humans , Immunoglobulin G/therapeutic use , Infliximab , Joints/immunology , Joints/pathology , Male , Middle Aged , Receptors, Tumor Necrosis Factor/therapeutic use , Retrospective Studies , Time Factors , Treatment Outcome
4.
Acta Oncol ; 46(2): 204-7, 2007.
Article in English | MEDLINE | ID: mdl-17453370

ABSTRACT

Widespread acceptance of breast conserving surgery for early breast cancer has led to renewed interest in multifocality, which is seen in 13-63% of breast cancers. According to current guidelines, oestrogen/progesterone receptor status is assessed on the sample obtained at initial core biopsy or the main tumour focus in multifocal breast cancer (more than one distinct tumour focus in a quadrant). We assessed receptor status of individual foci in multifocal breast cancer. Mastectomy specimens for 18 cases of multifocal breast cancer were identified. Immunohistochemical staining for oestrogen and progesterone receptors was performed on all tumour foci. On histological examination 11 patients demonstrated two independent tumour foci, three demonstrated three foci and four demonstrated four foci. Minor differences in oestrogen receptor score were seen between foci (attributed to the subjective nature of the scoring system), which did not affect the overall positive/negative classification. Sixteen patients (88%) were oestrogen receptor-positive. Progesterone receptor staining showed more variability between foci in two patients but, since the tumours were oestrogen receptor-positive this would not have affected clinical decision-making. No major differences in oestrogen receptor status between multiple tumour foci in the same quadrant were found in this pilot study.


Subject(s)
Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Female , Humans , Immunohistochemistry , Prognosis
5.
J Clin Pathol ; 60(2): 216-7, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17264248

ABSTRACT

A robust method to facilitate rapid laser microdissection and pressure catapulting (LMPC) coupled with direct polymerase chain reaction (dPCR) to eliminate the need for extraction of DNA before a PCR-based assay is described. This sequential LMPC-dPCR method is rapid and decreases the number of processing steps, reducing the chance of tissue loss and contamination.


Subject(s)
Microdissection/methods , Polymerase Chain Reaction/methods , Formaldehyde , Humans , Lasers , Microsatellite Repeats , Paraffin Embedding , Tissue Fixation/methods
6.
Br J Cancer ; 92(12): 2185-9, 2005 Jun 20.
Article in English | MEDLINE | ID: mdl-15928664

ABSTRACT

Early stage laryngeal cancer can be effectively cured by radiotherapy or conservative laryngeal surgery. In the UK, radiotherapy is the preferred first line treatment. However, up to 25% of patients with T2 tumours will demonstrate locally persistent or recurrent disease at the original site, requiring salvage surgery to achieve a definitive cure. Patients experiencing treatment failure have a relatively poor prognosis. A retrospective analysis was conducted consisting of 124 patients with early stage (T1-T2, N0) laryngeal squamous cell carcinoma. In total, 62 patients who failed radiotherapy were matched for T stage, laryngeal subsite and smoking history to a group of 62 patients successfully cured by radiotherapy. Using immunohistochemistry the groups were compared for expression of apoptotic proteins: bcl-2, bcl-X(L), bax, bak and survivin. Radioresistant laryngeal cancer was associated with bcl-2 (P < 0.001) and bcl-X(L) (P = 0.005) expression and loss of bax expression (P = 0.012) in pretreatment biopsies. Bcl-2 has an accuracy of 71% in predicting radiotherapy outcome. The association between expression of bcl-2, bcl-X(L) and bax with radioresistant cancer suggests a potential mechanism by which cancer cells avoid the destructive effects of radiotherapy. Predicting radioresistance, using bcl-2, would allow the clinician to recommend conservative laryngeal surgery as an alternative first line treatment to radiotherapy.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/radiotherapy , Genes, bcl-2/physiology , Laryngeal Neoplasms/metabolism , Laryngeal Neoplasms/radiotherapy , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Radiation Tolerance/physiology , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/surgery , Female , Humans , Inhibitor of Apoptosis Proteins , Laryngeal Neoplasms/surgery , Laryngectomy , Male , Microtubule-Associated Proteins/biosynthesis , Middle Aged , Neoplasm Proteins/biosynthesis , Predictive Value of Tests , Retrospective Studies , Survivin , Treatment Failure
7.
Eur J Cancer ; 41(11): 1645-8, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15964184

ABSTRACT

The expression of cyclooxygenase 2 (COX-2) protein is increased in many tumours and may be associated with a more aggressive phenotype. We aimed to assess COX-2 expression in a large series of archival mesothelioma specimens. Archival tissue was obtained from 86 malignant pleural mesothelioma samples (histological subtype: 42 epithelial, 28 biphasic and 16 sarcomatoid). Overexpression of COX-2 was detected by immunohistochemical analysis. Positive staining was located in the cytoplasm of malignant tumour cells. Overall 51/86 (59%) tumour sections demonstrated COX-2 overexpression. The frequency varied with histological subtype with 31/42 (73%) of epithelial sections, 14/28 (50%) of biphasic sections and 6/16 (37%) of sarcomatoid sections recorded as positive. Kaplan Meier survival analysis indicated that overexpression of COX-2 was significantly related to improved prognosis (P < 0.001) and was an independent prognostic factor in multivariant analysis. Overexpression of COX-2 protein may confer a survival advantage in mesothelioma patients.


Subject(s)
Mesothelioma/metabolism , Pleural Neoplasms/metabolism , Prostaglandin-Endoperoxide Synthases/metabolism , Adult , Aged , Aged, 80 and over , Cyclooxygenase 2 , Female , Humans , Immunohistochemistry , Male , Membrane Proteins , Mesothelioma/mortality , Middle Aged , Pleural Neoplasms/mortality , Prognosis , Regression Analysis , Survival Analysis
8.
Gut ; 54(5): 636-42, 2005 May.
Article in English | MEDLINE | ID: mdl-15831908

ABSTRACT

BACKGROUND AND AIMS: Germline mutations in mismatch repair (MMR) genes cause a greatly increased risk of cancer of the gastrointestinal and female reproductive tracts (hereditary non-polyposis colorectal cancer (HNPCC)). Loss of MMR expression is common in colorectal cancer (CRC) overall. Such loss is assumed to be acquired predominantly, although a population of CRC cases will include individuals with unrecognised MMR mutations. This study examines the association between MMR gene expression and family history of cancer among the CRC population. METHODS: Individuals with CRC were identified from two well characterised populations: (1) consecutive hospital patients (n = 644) and (2) a population based cases series (n = 249). CRC was examined for expression of hMLH1 and hMSH2 using immunohistochemistry, and expression was related to family history using logistic regression. RESULTS: hMLH1 and hMSH2 expression was assessed in 732 CRCs with 8% showing loss of expression. No association was seen overall for hMLH1 or hMSH2 expression and family history of CRC. Loss of hMSH2 was predicted by family history of extracolonic cancer (odds ratio (OR) 5.78 (95% confidence interval (CI) 0.95-35.18)) and family history suggestive of HNPCC (OR 27.84 (95% CI 4.37-177.56)). Loss of hMLH1 was not predicted by family history of extracolonic cancer or a family history suggestive of HNPCC but was for a family history of at least two affected relatives (OR 4.88 (95% CI 1.25-19.03)). CONCLUSIONS: Individuals with hMSH2 deficient CRC in the general population exhibit a family history and other characteristics suggestive of HNPCC, and may carry germline MMR mutations. Loss of hMLH1 is only associated with a strong family history of extracolonic cancer at older ages, suggesting a novel mechanism of susceptibility.


Subject(s)
Base Pair Mismatch/genetics , Colorectal Neoplasms/genetics , DNA Repair , Adaptor Proteins, Signal Transducing , Adult , Age Factors , Aged , Aged, 80 and over , Carrier Proteins , Case-Control Studies , Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , DNA, Neoplasm/genetics , DNA-Binding Proteins/metabolism , Family , Female , Germ-Line Mutation , Humans , Logistic Models , Male , Microsatellite Repeats/genetics , Middle Aged , MutL Protein Homolog 1 , MutS Homolog 2 Protein , Neoplasm Proteins/metabolism , Nuclear Proteins/metabolism , Proto-Oncogene Proteins/metabolism
9.
Clin Otolaryngol ; 30(2): 164-8, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15839869

ABSTRACT

OBJECTIVES: Radiotherapy is one of the principal treatment modalities for many types of head and neck tumour; what effects the dendritic cell (DC) population may have on treatment outcome have not been critically evaluated in laryngeal cancer. DESIGN: Retrospective, case-controlled study using immunohistochemistry to investigate the presence of S-100 positive DC in pre-treatment, archival biopsy tissue of early stage laryngeal cancers. SETTING: Patients with laryngeal cancer treated with radiotherapy in Head and Neck Departments in England. PARTICIPANTS: Patients diagnosed with early stage laryngeal cancer, treated with single modality radiotherapy with curative intent. Radioresistant tumours (n = 22), defined as recurrent tumours within 12 months of therapy. Radiosensitive tumours (n = 22), defined as no recurrence with a minimum follow-up of 36 months. MAIN OUTCOME MEASURES: Density of S-100 staining DC on three x200 magnified microscopic fields. RESULTS: DC were present in approximately equal numbers in both radioresistant and radiosensitive laryngeal tumour pre-treatment biopsies and therefore density did not correlate with radiotherapy treatment outcome (P = 0.420). CONCLUSION: There is no intrinsic deficiency in DC number in radioresistant laryngeal tumours meaning that such tumours could potentially benefit from vaccination strategies that enhance the specific anti-tumour immune response.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Dendrites/radiation effects , Laryngeal Neoplasms/radiotherapy , Biopsy , Carcinoma, Squamous Cell/pathology , Case-Control Studies , Cell Count , Female , Follow-Up Studies , Humans , Immunohistochemistry , Laryngeal Neoplasms/pathology , Male , Middle Aged , Radiotherapy Dosage , Retrospective Studies
10.
Clin Otolaryngol Allied Sci ; 29(6): 705-8, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15533164

ABSTRACT

Survival rates for head and neck cancer are comparatively poor, typically 40% at 5 years. Radiotherapy is one of the most common modalities used to cure early-stage cancers. It has the advantage in that it preserves anatomical structure and function. However, treatment failures do occur necessitating salvage surgery if a cure is to be achieved. A universally accepted definition of radioresistant cancer does not exist. Second primaries and occult metastasis are common in head and neck cancer, and can be confused with true radioresistant tumours. We suggest a strict definition for radioresistant laryngeal cancer and characterize 66 radioresistant tumours stage matched to 66 radiosensitive tumours. It was not possible to differentiate the radioresistant group from the radiosensitive groups using tumour differentiation. By using an agreed set of criteria defining radioresistant head and neck tumours, researchers will be better able to investigate molecular and cellular markers of radioresistance.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Laryngeal Neoplasms/radiotherapy , Radiation Tolerance/physiology , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/surgery , Female , Humans , Laryngeal Neoplasms/mortality , Laryngeal Neoplasms/surgery , Male , Middle Aged , Salvage Therapy/methods , Survival Rate , Treatment Failure
11.
Breast ; 13(6): 452-60, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15563851

ABSTRACT

Radiotherapy plays an important role in the management of breast cancer. Whilst its role in achieving local control following surgery in patients with early stage cancer is well established, there is still unclear evidence to explain the factors governing radioresistance in patients who develop recurrences both in the breast and axilla. Radiotherapy induces damage to the DNA. Various cell cycle damage check points and DNA damage repair pathways have been demonstrated. Ataxia telangiectasia mutant (ATM) kinase, which is a member of phosphatidylinositol-3 kinase (PI-3K) family appears to play a central role in DNA damage check point pathways. Over-expression of Insulin like growth factor-I receptor (IGF-IR), Human Epidermal Growth factor receptors (HERS), Vascular Endothelial growth factor (VEGF) on the cell surface and increased concentration of Epidermal Growth factor in the extracellular fluid have been associated with radioresistance. Specific genes such as p53, BRCA, Bcl-2 and chromosomal characteristics like telomere lengths have also been identified as playing significant roles in radiation responsiveness of a cell. This article reviews the current data on general principles of radiotherapy, the cellular mechanisms that operate in response to radiation damage and various molecular markers, intranuclear and extranuclear which have been demonstrated to influence radiation sensitivity in breast cancer cells.


Subject(s)
Breast Neoplasms/radiotherapy , Ataxia Telangiectasia Mutated Proteins , BRCA2 Protein/genetics , Breast Neoplasms/metabolism , Carrier Proteins/genetics , Cell Cycle Proteins , DNA Damage , DNA-Binding Proteins , ErbB Receptors/metabolism , Humans , Protein Serine-Threonine Kinases/physiology , Proto-Oncogene Proteins c-bcl-2/metabolism , Receptor, IGF Type 1/metabolism , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins , Ubiquitin-Protein Ligases
12.
Int J Oncol ; 25(2): 277-83, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15254723

ABSTRACT

The aim of this study was to characterise cytogenetically, breast cancer cell lines and primary tumours to identify chromosomal regions of interest in breast cancer. Multicolour fluorescence in situ hybridization (MFISH) and comparative genomic hybridization (CGH) were used to karyotype five established breast cancer cell lines and two short-term primary tumour cultures. Chromosome 8 was identified as a frequent target for aberrations in all cell lines and one primary culture by MFISH and CGH. CGH identified frequent gains of 1q (all samples) and 14q (all cell lines) and deletion of 22q (all samples). MFISH revealed a t(9;17) translocation in both primary tumours and the T47D cell line. MFISH analysis of the cell lines revealed a significant number of translocations previously unidentified in other studies using similar techniques, highlighting the necessity of utilising data from both primary cultures and established cell lines when investigating complex cytogenetic aberrations using MFISH and CGH.


Subject(s)
Breast Neoplasms/genetics , Chromosome Aberrations , Chromosome Painting , Breast Neoplasms/diagnosis , Cells, Cultured , Female , Humans , Translocation, Genetic
13.
Br J Cancer ; 90(10): 1976-82, 2004 May 17.
Article in English | MEDLINE | ID: mdl-15138481

ABSTRACT

Survival from head and neck squamous cell carcinoma (HNSCC) has remained static for the last 20 years. The development of lymph node metastasis (LNM) significantly reduces the 5-year survival rate, thus the ability to identify tumours with the potential to metastasise would allow more aggressive treatment regimes to be directed at these patients regardless of negative clinical and radiological findings at the time of presentation. Comparative genomic hybridisation (CGH) can identify chromosomal aberrations that may lead to metastasis. DNA from 23-paired specimens of primary tumour (PT) and LNM were analysed. Nonrandom copy number changes were identified in all paired samples. Similar numbers of aberrations were identified on PT and LNM samples. The most common aberrations were 3q (90%), 8q (65%), 1q (50%), 5p (43%), 2q (41%) and 11q (41%) and deletions 3p (57%), 1p (54%), 4p (48%), 13q (48%), 11q (41%) and 10q (37%). A number of differences were also detected. No aberration was found to be preferentially associated with the LNM, although gains on 6q (48 vs 22%) and 22q (26 vs 9%) were found at higher frequencies. Clonality studies demonstrated that LNM develop from the dominant population of cells in the PT. These results were compared with two similar publications. No combination of chromosomal aberrations, as detected by CGH, was associated with metastatic progression in HNSCC.


Subject(s)
Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Chromosome Aberrations , DNA, Neoplasm/genetics , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/pathology , Lymphatic Metastasis , Adult , Aged , Female , Humans , Male , Middle Aged , Nucleic Acid Hybridization , Prognosis , Survival Analysis
14.
Ann Oncol ; 15(5): 797-801, 2004 May.
Article in English | MEDLINE | ID: mdl-15111350

ABSTRACT

BACKGROUND: Radiotherapy is the principal modality used to treat early stage laryngeal cancer. Unfortunately treatment failures occur in 10-25% of patients. Subsequent salvage surgery is technically more difficult, with increased complication and failure rates. The ability to predict or prevent radioresistance would improve the poor survival associated with this disease. Cox-2 is an inducible enzyme involved with prostaglandin synthesis. We investigated a potential role for Cox-2 in predicting radioresistance in laryngeal cancer. PATIENTS AND METHODS: Using immunohistochemical techniques we examined the expression of Cox-2 protein in 122 pre-treatment laryngeal biopsies. All tumours were treated with single modality radiotherapy (curative intent). The group comprised of 61 radioresistant and 61 radiosensitive tumours matched for T stage, laryngeal subsite, gender and smoking history. RESULTS: Cox-2 expression was detected in 41 of 61 (67%) biopsy samples from patients with radioresistant tumours and 25 of 61 (41%) radiosensitive tumours. Overexpression was significantly associated with radioresistant tumours (P = 0.004). Cox-2 has a 67% accuracy in predicting radiotherapy failure. CONCLUSION: Cox-2 may have prognostic value in predicting response to radiotherapy. Cox-2 inhibitors such as NS-398 have been shown to enhance the effects of radiotherapy. We suggest that their use may be beneficial in patients who are destined to fail radiotherapy.


Subject(s)
Biomarkers, Tumor/analysis , Isoenzymes/analysis , Isoenzymes/biosynthesis , Laryngeal Neoplasms/enzymology , Laryngeal Neoplasms/radiotherapy , Prostaglandin-Endoperoxide Synthases/analysis , Prostaglandin-Endoperoxide Synthases/biosynthesis , Radiation Tolerance/physiology , Aged , Biopsy , Cyclooxygenase 2 , Female , Humans , Immunohistochemistry , Male , Membrane Proteins , Middle Aged , Peroxidases , Predictive Value of Tests , Prognosis , Prostaglandins/biosynthesis , Retrospective Studies
15.
Clin Otolaryngol Allied Sci ; 29(2): 105-14, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15113291

ABSTRACT

Early stage squamous cell carcinoma of the larynx can be effectively cured by radiotherapy. Unfortunately treatment failures do occur and at present cannot be predicted by the clinician. This article reviews the potential molecular and cellular markers that may help to predict radioresistance in early stage laryngeal cancer.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/radiotherapy , Laryngeal Neoplasms/radiotherapy , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Genetic Markers , Humans , Laryngeal Neoplasms/genetics , Laryngeal Neoplasms/metabolism , Predictive Value of Tests , Treatment Failure
16.
Br J Cancer ; 90(4): 900-5, 2004 Feb 23.
Article in English | MEDLINE | ID: mdl-14970871

ABSTRACT

The cytogenetic abnormalities in non-small-cell lung cancer remain elusive due primarily to the difficulty in obtaining metaphase spreads from solid tumours. We have used the molecular cytogenetic techniques of multicolour fluorescent in situ hybridisation (M-FISH) and comparative genomic hybridisation (CGH) to analyse four primary non-small-cell lung cancer samples and two established cell lines (COR-L23 and COR-L105) in order to identify common chromosomal aberrations. CGH revealed regions on 5p, 3q, 8q, 11q, 2q, 12p and 12q to be commonly over-represented and regions on 9p, 3p, 6q, 17p, 22q, 8p, 10p, 10q and 19p to be commonly under-represented. M-FISH revealed numerous complex chromosomal rearrangements. Translocations between chromosomes 5 and 14, 5 and 11 and 1 and 6 were observed in three of the six samples, with a further 14 translocations being observed in two samples each. Loss of the Y chromosome and gains of chromosomes 20 and 5p were also frequent. Chromosomes 4, 5, 8, 11, 12 and 19 were most frequently involved in interchromosomal translocations. Further investigation of the recurrent aberrations will be necessary to identify the specific breakpoints involved and any role they may have in the aetiology, diagnosis and prognosis of non-small-cell lung cancer.


Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Chromosome Aberrations , Lung Neoplasms/genetics , Aged , Cell Transformation, Neoplastic , Diagnosis, Differential , Female , Humans , In Situ Hybridization, Fluorescence , Karyotyping , Lung Neoplasms/pathology , Male , Middle Aged , Nucleic Acid Hybridization , Prognosis , Translocation, Genetic
17.
Br J Cancer ; 89(5): 864-9, 2003 Sep 01.
Article in English | MEDLINE | ID: mdl-12942119

ABSTRACT

A total of 45 primary head and neck squamous cell carcinomas were analysed by comparative genomic hybridisation to identify regions of chromosomal deletion and gain. Multiple regions of copy number aberration were identified including gains affecting chromosomes 3q, 8q, 5p, 7q, 12p and 11q and deletion of material from chromosomes 3p, 11q, 4p, 5q, 8p, 10q, 13q and 21. Kaplan-Meier survival analysis revealed significant correlations between gain of 3q25-27 and deletion of 22q with reduced disease-specific survival. In addition, gain of 17q and 20q, deletion of 19p and 22q and amplification of 11q13 were significantly associated with reduced disease-free survival. A Cox proportional hazards regression model identified deletion of 22q as an independent prognostic marker. The data presented here provide further evidence that the creation of a genetically based tumour classification system will soon be possible, complementing current histopathological characterisation.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma, Squamous Cell/genetics , Chromosome Aberrations , DNA, Neoplasm/analysis , Head and Neck Neoplasms/genetics , Carcinoma, Squamous Cell/mortality , Chromosome Mapping , Disease-Free Survival , Female , Head and Neck Neoplasms/mortality , Humans , Lymphatic Metastasis , Male , Nucleic Acid Hybridization , Prognosis , Proportional Hazards Models
18.
Int J Cancer ; 102(3): 230-6, 2002 Nov 20.
Article in English | MEDLINE | ID: mdl-12397641

ABSTRACT

Small cell lung cancer (SCLC) is a major cause of cancer related morbidity and mortality. Karyotypic studies have revealed numerous chromosomal aberrations in most SCLC however, classical G-banding analysis is unable to fully characterise complex marker chromosomes. Recent developments in molecular cytogenetics now allow accurate identification of the chromosomal components of complicated rearrangements. We have applied the technique of multicolour fluorescence in situ hybridization (M-FISH) in combination with comparative genomic hybridization (CGH) to the analysis of 5 SCLC cell lines and 1 primary tumour specimen to characterise the chromosomal abnormalities. CGH analysis identified many similarities between specimens, with frequent DNA copy number decreases on chromosomes 3p, 5q, 10, 16q, 17p and frequent gains on 3q, 1p, 1q and 14q. In contrast, M-FISH analysis revealed a large number of structural abnormalities, with each specimen demonstrating an individual pattern of chromosomal translocations. Forty different translocations were identified with the vast majority (39) being unbalanced. Chromosome 5 was the most frequently rearranged chromosome (9 translocations) followed by chromosomes 2, 10 and 16 (6 translocations each). Further investigation of these frequently involved chromosomes is warranted to establish whether consistent break points are involved in these translocations, causing dysregulation of specific genes that are crucial for tumour progression and secondly to identify the affected genes.


Subject(s)
Carcinoma, Small Cell/genetics , Carcinoma, Small Cell/metabolism , Chromosome Aberrations , Lung Neoplasms/genetics , Cell Line , Chromosomes/ultrastructure , DNA/ultrastructure , Humans , In Situ Hybridization, Fluorescence , Karyotyping , Metaphase , Nucleic Acid Hybridization , Tumor Cells, Cultured
19.
Int J Oncol ; 20(3): 489-94, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11836559

ABSTRACT

The breast cancer cell line MCF-7 is a widely used model in breast cancer research however a number of conflicting reports have been published regarding its biological properties. We hypothesised that there will be significant in vitro mutation and genotypic evolution over time in this cell line. To assess the genetic divergence of MCF-7 at the chromosomal level, we analysed MCF-7 cell lines grown independently at three different laboratories using M-FISH and CGH. In addition, MCF-7 cells from our own laboratory were also analysed at two time points 18 months apart. Several common chromosomal translocations were identified in all variants of the cell lines. In addition, a significant number of unique abnormalities were identified, characterising each of the variants studied. Genotypic differences between cell lines grown independently in different laboratories would significantly alter the phenotypic characteristics of each cell line rendering biological properties inconsistent between laboratories.


Subject(s)
Breast Neoplasms/genetics , In Situ Hybridization, Fluorescence/methods , Breast Neoplasms/metabolism , Chromosome Aberrations , Chromosomes/ultrastructure , Female , Genotype , Humans , Karyotyping , Metaphase , Nucleic Acid Hybridization , Time Factors , Translocation, Genetic , Tumor Cells, Cultured
20.
Mol Pathol ; 53(1): 51-2, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10884923

ABSTRACT

The extraction of DNA from formalin fixed, paraffin wax embedded tissue can be problematical, with long protocols producing low yields. This report describes a very simple and useful method for amplifying DNA from formalin fixed, paraffin wax embedded tissue without the need for prior DNA extraction. This method allows direct polymerase chain reaction (PCR) based molecular analysis of fixed tissue. It is an invaluable method if clinical biopsy specimens are to be investigated, because extraction of uncontaminated DNA from such small samples can be very difficult or even impossible. It will also facilitate the study of intratumour heterogeneity, with the analysis of multiple small areas from within a single tumour section. In addition, this method can be used for other samples where only a few tests are to be carried out and a stock of DNA is not required, thus shortening the analysis time.


Subject(s)
Fluorescence , Polymerase Chain Reaction/methods , Biopsy , Clinical Protocols , Formaldehyde , Humans , Paraffin Embedding
SELECTION OF CITATIONS
SEARCH DETAIL
...